ReviewMicroorganisms2022
The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.
Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- The airway mycobiome in chronic respiratory diseases: current advances and future frontiers.Journal of translational medicine · 2025Review
- Impact of Antibiotic Therapy on the Upper Respiratory Tract and Gut Mycobiome in Patients with Cystic Fibrosis.Journal of fungi (Basel, Switzerland) · 2025Article
- Oral microbiota and respiratory diseases: advances and perspectives.Clinical microbiology reviews · 2025Review
- The Respiratory Tract Microbiome and Human Health.Microbial biotechnology · 2025Review
- Lung Microbiota: From Healthy Lungs to Development of Chronic Obstructive Pulmonary Disease.International journal of molecular sciences · 2025Review
- Correlation BetweenJournal of fungi (Basel, Switzerland) · 2025Article
- Insights into human respiratory microbiome under dysbiosis and its analysis tool.Frontiers in microbiomes · 2025Review
- Tripartite exacerbation stratification in AECOPD suggests a gradient of lower airway dysbiosis: a metagenomic transition from commensal taxa toFrontiers in microbiology · 2025Article
- Characterization of the oral mycobiome of Portuguese with allergic rhinitis and asthma.Current research in microbial sciences · 2024Article
- A mass spectrometry-based strategy for investigating volatile molecular interactions in microbial consortia: unveiling aFrontiers in microbiology · 2024Article
- The airway mycobiome and interactions with immunity in health and chronic lung disease.Oxford open immunology · 2024Review
- Bacteria and fungi of the lung: allies or enemies?Frontiers in pharmacology · 2024Review
- The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus onLife (Basel, Switzerland) · 2023Review
- Editorial of Special Issue "Human Pathogenic Fungi: Host-Pathogen Interactions and Virulence".Microorganisms · 2023Article
- Immunopathologic Role of Fungi in Chronic Rhinosinusitis.International journal of molecular sciences · 2023Review
- Microbiome and Asthma: Microbial Dysbiosis and the Origins, Phenotypes, Persistence, and Severity of Asthma.Nutrients · 2023Review
- Upper respiratory tract mycobiome alterations in different kinds of pulmonary disease.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Microbes play an important role in the pathogenesis of chronic lung diseases, such as chronic obstructive pulmonary disease, cystic fibrosis, non-cystic fibrosis bronchiectasis, and asthma. While the role of bacterial pathogens has been extensively studied, the contribution of fungal species to the pathogenesis of chronic lung diseases is much less understood. The recent introduction of next-generation sequencing techniques has revealed the existence of complex microbial lung communities in healthy individuals and patients with chronic respiratory disorders, with fungi being an important part of these communities' structure (mycobiome). There is growing evidence that the components of the lung mycobiome influence the clinical course of chronic respiratory diseases, not only by direct pathogenesis but also by interacting with bacterial species and with the host's physiology. In this article, we review the current knowledge on the role of fungi in chronic respiratory diseases, which was obtained by conventional culture and next-generation sequencing, highlighting the limitations of both techniques and exploring future research areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.